iothalamate-meglumine and Headache

We compared Hexabrix 320 (580 mOsm kg-1) with Conray 420 (2500 mOsm kg-1) for left ventriculography using a prospective randomised double-blind protocol. One hundred consecutive patients with suspected coronary disease were assigned to Hexabrix (52) or Conray (48) for left ventriculography (dose 10 ml m-2 BSA; flow rate 12 ml s-1). Thirteen patients found Hexabrix unpleasant compared with 24 receiving Conray; overall the feelings of warmth and discomfort were less with Hexabrix than Conray (p less than 0.01 and p less than 0.02 respectively). The incidence of nausea, vomiting, and hypersensitivity was similar. Angiographic quality was better with Conray than with Hexabrix (p less than 0.05). Average changes in heart rate and systolic pressure were similar, though there was greater variation in systolic pressure change after Conray (p less than 0.025). End diastolic pressure increased more after Conray than after Hexabrix (p less than 0.05). These slight advantages of Hexabrix over Conray may be valuable in patients requiring multiple angiograms or in those with impaired cardiac function, but do not justify its use for routine angiography.

Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Contrast Media; Coronary Disease; Female; Headache; Heart Rate; Humans; Iodobenzoates; Iothalamate Meglumine; Ioxaglic Acid; Male; Middle Aged; Osmolar Concentration; Radiography; Triiodobenzoic Acids

The rate of side effects, the results of EMG, EEG and CSF changes after radiculography, the rates of late leptomeningeal changes and the details of the hyperosmolality following the ionic contrast media are recorded and discussed. In conclusion rules are presented for the choice of contrast medium and the examination technic for radiculography.

Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Contrast Media; Double-Blind Method; Female; Headache; Humans; Iothalamate Meglumine; Male; Metrizamide; Middle Aged; Myelography; Osmolar Concentration

Metrizamide and meglumine iocarmate (Dimer-X), which at present are the contrast media for myelography best tolerated by central nervous system, were compared in a double-blind test comprising a total of 86 patients, all with symptoms of lumbar or sacral root involvement. Symptoms appearing were recorded using a standard interview formula 24 hoaurs after myelography. EEG, routine laboratory analyses of CSF and neurologic examinations were also made. In some cases CSF paper electrophoresis, CSF pressure recordings and determination of CSF iodine content were obtained.

Topics: Adult; Aerophagy; Aged; Blood Cell Count; Clinical Trials as Topic; Contrast Media; Female; Headache; Humans; Iodobenzoates; Iothalamate Meglumine; Iothalamic Acid; Male; Metrizamide; Middle Aged; Myelography; Pain; Spinal Cord Diseases

An attempt was made to reduce the side effects associated with the use of Metrizamide in lumbar radiculography by the removal of the contrast medium on completion of the examination. Almost complete removal was achieved in 103 patients and of these 73% had no symptoms after examination, while 8% had severe symptoms. Eleven of 14 patients in whom removal was not attempted or was not successful had significant symptoms after examination. It is concluded that aspiration of Metrizamide will reduce the incidence and severity of the side effects associated with the use of this contrast medium.

Topics: Contrast Media; Headache; Humans; Iothalamate Meglumine; Metrizamide; Myelography; Spinal Nerve Roots; Spinal Puncture; Subtraction Technique; Time Factors

Topics: Acute Disease; Contrast Media; Headache; Humans; Iothalamate Meglumine; Meningitis; Nausea; Solubility; Vomiting; Water

The adverse effects in a series of 50 lumbar myelographies with Amipaque were compared with those in a corresponding series, examined with Dimer-X. Side effects occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in either series but slight fibrillations of fasciculations appeared in 2 Dimer-X patients. Hyperreflexia of the legs was recorded in 22% of the Amipaque and in 36% of the Dimer-X cases. Other adverse reactions to the media were mild to moderate. Some burst activity, but no definite paroxysmal abnormality was noted in EEG recordings in 2 Amipaque cases. The low epileptogenicity of Amipaque has ensured a wider safety margin of lumbar myelography.

Topics: Adult; Aged; Brain; Diazepam; Drug Evaluation; Electroencephalography; Female; Fever; Headache; Humans; Iodobenzoates; Iothalamate Meglumine; Iothalamic Acid; Lumbosacral Region; Male; Metrizamide; Middle Aged; Myelography; Nausea; Pain; Premedication; Seizures

In a comparative study between Dimer X and Amipaque (metrizamide) for lumbar myelography it was found that there is a little higher frequency of monor, but unimportant side effects after Amipaque. Amipaque has also been used for thoracocervical myelography with excellent results and without greater discomfort than after myelography in the lumbar region. A new puncture technique was used for the eximation of the cervical region alone: lateral puncture on the neck between the laminae of C1 and C2 under TV control. In more than 75 reinvestigations no arachnoid changes were observed.

Topics: Adult; Aged; Female; Fever; Headache; Humans; Iodobenzoates; Iothalamate Meglumine; Iothalamic Acid; Lumbosacral Region; Male; Metrizamide; Middle Aged; Myelography; Nausea; Neck; Seizures; Subarachnoid Space; Surveys and Questionnaires; Urination Disorders; Vomiting

Lumbar myelography with dimeglumine iocarmate was performed in 90 cases premedicated with diazepam (Valium). EEG was performed before, as well as 3 and 24 hours after myelography. The use of diazepam interfered to some extent with the interpretation of the EEG. In 3 cases EEG abnormalities occurred 3 hours after myelography, most probably ascribable to Dimer-X. No further changes were found in the 24-hour recording. Immediate side effects were few and mild and seizures did not appear. The EEG abnormalities were equally distributed among patients with and without side effects.

Topics: Adolescent; Adult; Aged; Electroencephalography; Female; Headache; Humans; Iothalamate Meglumine; Iothalamic Acid; Male; Middle Aged; Myelography; Nausea; Pain; Seizures; Time Factors

Topics: Cerebral Ventriculography; Contrast Media; Drug Tolerance; Electroencephalography; Electromyography; Headache; Humans; Iodobenzoates; Iothalamate Meglumine; Metrizamide; Myelography; Nausea; Vomiting

Topics: Adolescent; Angiocardiography; Arrhythmias, Cardiac; Bronchial Spasm; Cardiac Catheterization; Child; Contrast Media; Cough; Dyspnea; Geriatrics; Headache; Heart Defects, Congenital; Humans; Hypotension; Infant; Infant, Newborn; Iothalamate Meglumine; Iothalamic Acid; Mortality; Pulmonary Edema; Taste; Toxicology; Urticaria; Vomiting